Mark E. Dmytruk - Sep 30, 2022 Form 4 Insider Report for Ginkgo Bioworks Holdings, Inc. (DNA)

Role: Chief Financial Officer
Signature: /s/ Karen Tepichin, Attorney-in-Fact
Stock symbol: DNA
Transactions as of: Sep 30, 2022
Transactions value $: -$22,660
Form type: 4
Date filed: 10/4/2022, 10:00 PM
Previous filing: Mar 14, 2022
Next filing: Nov 7, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DNA	Class A Common Stock	Options Exercise		+16.4K			16.4K	Sep 30, 2022	Direct	F1, F2
transaction	DNA	Class A Common Stock	Sale	-$22.7K	-7.26K	-44.37%	$3.12	9.1K	Oct 3, 2022	Direct	F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DNA	Class B Common Stock	Options Exercise		-16.4K	-2.43%		658K	Sep 30, 2022	Class A Common Stock			Direct	F1, F2, F4

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the conversion of shares of Class B Common Stock to shares of Class A Common Stock.
F2	Shares of the Class B Common Stock may be converted into shares of Class A Common Stock, on a one-to-one basis, at the option of the holder at any time and have no expiration date.
F3	Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of equity securities of the Issuer. Sales to cover tax withholding obligations in connection with the vesting of such securities do not represent discretionary trades by the Reporting Person. The Issuer's equity incentive plans allow the Issuer to require that satisfaction of tax withholding obligation to be funded by a "sell to cover" transaction.
F4	Includes shares of Class B Common Stock that are subject to vesting conditions.

Remarks:

Chief Financial Officer